Ovarian cancer drug to enter phase II clinical trial
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.
May 5, 2023
0
3
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.
May 5, 2023
0
3
Should patients over the age of 70 with head and neck cancer receive aggressive combined radiotherapy and chemotherapy? This is a controversial issue among patients, their families and health professionals. A large-scale ...
Apr 26, 2023
0
6
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented ...
Apr 25, 2023
0
5
For people with cancer, chemotherapy saves lives, but for some patients, the treatment comes with a side effect—heart damage. Screening cancer drugs for cardiotoxicity has been an ongoing challenge, as heart cells don't ...
Apr 20, 2023
0
16
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center reports benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or ...
Apr 18, 2023
0
2
A recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center, demonstrated that a new chemotherapy combination—trifluridine/tipiracil (FTD/TPI) ...
Apr 18, 2023
0
1
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
4
Chemotherapy is associated with an increased risk of treatment-related heart damage, including heart failure and cerebrovascular disease, for many patients. But a new meta-analysis, presented at the American College of Cardiology's ...
Apr 14, 2023
0
2
A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published ...
Apr 13, 2023
0
4
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
9